Editorial
Targeting gene fusions in non-small cell lung cancer—a ceaseless success story?
Translational Lung Cancer Research
2023;
12
(7)
:1358-1360
.
(31 July 2023)
Low level ALK FISH positive results should be approached with caution and confirmed by an orthogonal method
Translational Lung Cancer Research
2023;
12
(7)
:1361-1363
.
(31 July 2023)
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer
Translational Lung Cancer Research
2023;
12
(7)
:1364-1368
.
(31 July 2023)
Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?
Translational Lung Cancer Research
2023;
12
(7)
:1369-1371
.
(31 July 2023)
Original Article
Radiomic signature accurately predicts the risk of metastatic dissemination in late-stage non-small cell lung cancer
Translational Lung Cancer Research
2023;
12
(7)
:1372-1383
.
(31 July 2023)
Does hyperthermic povidone-iodine lavage increase the apoptotic rate of residual cancer cell in patients with malignant pleural mesothelioma?—a prospective pilot study
Translational Lung Cancer Research
2023;
12
(7)
:1384-1390
.
(31 July 2023)
Patient-reported impact of symptoms in lung cancer (PRISM-LC)
Translational Lung Cancer Research
2023;
12
(7)
:1391-1413
.
(31 July 2023)
Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC
Translational Lung Cancer Research
2023;
12
(7)
:1414-1424
.
(31 July 2023)
A prospective phase 2 study of expeditious EGFR genotyping and immediate therapeutic initiation through extracellular vesicles (EV)-based bronchoalveolar lavage fluid (BALF) liquid biopsy in advanced NSCLC patients
Translational Lung Cancer Research
2023;
12
(7)
:1425-1435
.
(31 July 2023)
Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective study
Translational Lung Cancer Research
2023;
12
(7)
:1436-1444
.
(31 July 2023)
Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy
Translational Lung Cancer Research
2023;
12
(7)
:1445-1453
.
(31 July 2023)
First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic
Translational Lung Cancer Research
2023;
12
(7)
:1454-1465
.
(31 July 2023)
Learning curve for uniportal thoracoscopic pulmonary segmentectomy: how many procedures are required to acquire expertise?
Translational Lung Cancer Research
2023;
12
(7)
:1466-1476
.
(31 July 2023)
Identification of lysosomal genes associated with prognosis in lung adenocarcinoma
Translational Lung Cancer Research
2023;
12
(7)
:1477-1495
.
(31 July 2023)
Diagnostic accuracy and safety of electromagnetic navigation transthoracic needle biopsy under moderate sedation for the diagnosis of peripheral pulmonary lesions
Translational Lung Cancer Research
2023;
12
(7)
:1496-1505
.
(31 July 2023)
Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy
Translational Lung Cancer Research
2023;
12
(7)
:1506-1516
.
(31 July 2023)
Overexpression of MRPL19 in predicting poor prognosis and promoting the development of lung adenocarcinoma
Translational Lung Cancer Research
2023;
12
(7)
:1517-1538
.
(31 July 2023)
Risk factors for pulmonary embolism in lung cancer patients with lower limb deep venous thrombosis: a case-control study
Translational Lung Cancer Research
2023;
12
(7)
:1539-1548
.
(31 July 2023)
Review Article
A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma
Translational Lung Cancer Research
2023;
12
(7)
:1549-1562
.
(31 July 2023)
Advancements of ALK inhibition of non-small cell lung cancer: a literature review
Translational Lung Cancer Research
2023;
12
(7)
:1563-1574
.
(31 July 2023)
Review of the use of radiomics to assess the risk of recurrence in early-stage non-small cell lung cancer
Translational Lung Cancer Research
2023;
12
(7)
:1575-1589
.
(31 July 2023)
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
Translational Lung Cancer Research
2023;
12
(7)
:1590-1610
.
(31 July 2023)
Case Report
Multiple bronchiolar adenomas/ciliated muconodular papillary tumors of the bilateral lung with tumor budding and potential malignant transformation into squamous cell carcinoma: a case report and literature review
Translational Lung Cancer Research
2023;
12
(7)
:1611-1624
.
(31 July 2023)
Editorial Commentary
Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation?
Translational Lung Cancer Research
2023;
12
(7)
:1625-1627
.
(31 July 2023)
Tarlatamab: a potential new option for recurrent small cell lung cancer
Translational Lung Cancer Research
2023;
12
(7)
:1628-1630
.
(31 July 2023)
Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
Translational Lung Cancer Research
2023;
12
(7)
:1631-1635
.
(31 July 2023)
Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail
Translational Lung Cancer Research
2023;
12
(7)
:1636-1642
.
(31 July 2023)
First-line management of advanced non-small-cell lung cancer: can we do better?
Translational Lung Cancer Research
2023;
12
(7)
:1643-1648
.
(31 July 2023)
ADAURA update: only the end of the beginning
Translational Lung Cancer Research
2023;
12
(7)
:1649-1651
.
(31 July 2023)
Future lung cancer prediction using low-dose chest computed tomography
Translational Lung Cancer Research
2023;
12
(7)
:1652-1654
.
(31 July 2023)
Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial
Translational Lung Cancer Research
2023;
12
(7)
:1655-1657
.
(31 July 2023)
